The role of lipocalin 2 (LCN2) in pulmonary hypertension (PH) in pediatric patients with congenital heart disease (CHD) remains unclear. We sought to investigate whether LCN2 could be a potential biomarker for PH in pediatric patients who underwent surgery for CHD. From December 2018 to February 2020, patients undergoing surgical repair for congenital defects with and without PH were identified. Healthy children without CHD and PH served as controls. A mean pulmonary artery pressure (mPAP) >20 mmHg was used as the definition of PH. Blood samples and echocardiograms were obtained in all patients and right heart catheterization was performed in 79 patients. Multivariable logistic regression analysis was used to determine potential predictors for PH. Among 102 patients, the median age was 10 (interquartile range [IQR] 7.0–13) months, and 37.5% were female. Compared to non-PH patients and controls, PH patients showed elevated levels of LCN2 (P < 0.001). In addition, LCN2 levels positively correlated with the invasive haemodynamic indices of PH. In univariate regression, LCN2 (odds ratio = 2.69 [1.06–5.31], P < 0.001), N-Terminal pro Brain Natriuretic Peptide (NT-proBNP) (OR = 1.91 [1.21–7.56], P = 0.03) and high-sensitive troponin T (hsTnT) (OR = 1.36 [1.01–3.57], P = 0.01) were associated with PH; however, only LCN2 (OR = 1.68 [1.04–4.52], P = 0.03) was significantly associated with PH on multivariate analysis. In conclusion, children with PH had increased LCN2 expression. LCN2 levels positively correlated with invasive indices of PH. These results indicate LCN2 could be a useful biomarker for prediction of PH in pediatric CHD cases.

Keywords
Congenital heart disease, Pulmonary hypertension, Lipocalin 2, Biomarkers

1. Introduction
Pulmonary hypertension (PH) is associated with poor prognosis in children with congenital heart disease (CHD) [1, 2]. Neurohormonal activation and endothelial dysfunction have been identified as important mechanisms in PH associated with CHD [3, 4]. Prior studies have observed that N-Terminal pro Brain Natriuretic Peptide (NT-proBNP) and high-sensitive troponin T (hsTnT) can be used to assess risk in patients with PH [5–8]. However, there is limited data regarding early prediction of PH in children with CHD [9].

Lipocalin 2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL, 25kDa), forms part of the lipocalin superfamily. It is involved in several pathophysiological processes, such as inflammation, epithelial mesenchymal transition and angiogenesis [10–12]. The level of LCN2 has been used to assess the extent of kidney tissue damage following pediatric cardiac surgery [13, 14]. Recent work using a rat model suggests that LCN2 may be linked to PH [15, 16]. Therefore, LCN2 may be a useful biomarker for early detection of PH in pediatric cases with CHD [9, 17]. In the present study, our aim was to assess the expression levels of LCN2, NT-proBNP and hsTnT in children with PH associated with CHD, and thus determine their ability to predict PH in pediatric patients undergoing surgery for CHD.

2. Methods
2.1 Study population
From December 2018 to February 2020, patients admitted for surgical repair of CHD were prospectively identified at Beijing Children's Hospital. Their ages ranged from 6 to 36 months. Patients with acute infection, sepsis, or renal failure were excluded, as well as those taking cardiotoxic medication [10, 16]. For standardization of the study, patients with more than moderate post-tricuspid shunts such as ventricular septal defect (VSD) and patent ductus arteriosus (PDA) were included. The threshold value for the definition of PH was a mean pulmonary artery pressure (mPAP) of >20 mmHg, as measured by right heart catheterization [18]. Patients were separated into those with CHD and PH, and those with CHD but without PH. Healthy children without PH and CHD
served as controls. Healthy controls were recruited from the Pediatric Cardiology Department, those who suspected heart murmur but found have no detectable cardiac abnormalities. All cases underwent physical examination by a cardiologist, and their medical history, medications and vital signs were recorded.

2.2 Transthoracic echocardiography

Echocardiography was conducted using a Philips iE33 ultrasound scanner (Philips Medical Systems, Amsterdam, Netherlands). Two-dimensional (2D) and Doppler echocardiography data were collected using 8 MHz or 3.5 MHz sector transducer and stored digitally on a QLAB work station for further analysis. The left ventricular ejection fraction (LVEF) was determined using the biplanar method of disks (modified Simpson’s rule). Data were measured over 5 heart-beats by two blinded external reviewers according to current guidelines [19]. We calculated z-scores for right ventricular (RV) wall dimension and adjusted for patient age and sex according to standard reference values [20].

2.3 Hemodynamic assessment

Cardiac catheterization prior to surgery was performed only in cases with CHD, and not in healthy controls. Hemodynamic measurements included pulmonary artery pressures, pulmonary capillary wedge pressure and right atrial pressure (RAP). The Fick equation was used to estimate systemic and pulmonary blood flows, while pulmonary vascular resistance was estimated using the standard equation of mean atrial pressure divided by flow. Cardiac catheterization was performed via a percutaneous femoral approach and low-dose midazolam and propofol were used for conscious sedation. Blood flow and vascular resistance were corrected for body surface area.

2.4 Laboratory analysis

Blood samples for biomarkers were stored at −80 °C until biomarker measurements were performed. The level of serum LCN2 was measured using enzyme-linked immunosorbent assay (ELISA) kit (R&D System, Minneapolis, MN, USA). This kit recognizes full-length human LCN2 within a concentration range of 0.156–10 ng/mL. Electrochemiluminescence immunoassay (Roche Diagnostics, Basel, Switzerland) was employed to measure serum NT-proBNP levels in fresh serum samples. Serum hsTnT levels were analyzed by the quantitative electrochemiluminescence immunoassay method using Elecsys 2010 (Roche Diagnostics, Mannheim, Germany).

2.5 Statistical analysis

Continuous variables with normal distribution were expressed as the mean (standard deviation [SD]). Non-normal variables were expressed as the median (interquartile range [IQR]). Categorical variables were expressed as numbers and percentages. Differences between groups were evaluated using one-way analysis of variance (ANOVA) for continuous variables and Kruskal-Wallis test for categorical variables. Pearson’s correlation test was used to evaluate correlations between variables. Possible predictors of PH were identified by univariate logistic regression. Statistically significant (P < 0.05) variables were selected for analysis in a multivariate logistic regression model. Receiver operating characteristic (ROC) curves were obtained for biomarkers that were predictive. Data were analyzed by SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) and a P-value of < 0.05 was considered to be statistically significant.

3. Results

3.1 Study population

A total of 102 patients (median age 10 [IQR 7.0–13.0] months) comprised the study cohort, of which 37.5% were female. Fifty-four patients had PH because of a left to right shunt, while 25 patients had a left to right shunt without PH. Twenty-three healthy children served as controls.

3.2 Patient characteristics

Table 1 shows the clinical characteristics for this study cohort. No significant differences in age, gender, body surface area, history of AKI, creatinine and urea nitrogen were observed between the three groups. The PH group had higher levels of LCN2 (9.2 [5.9, 12.3] vs. 6.2 [5.3, 8.9] vs. 5.3 [4.6, 6.6], P < 0.001), NT-proBNP (569 [431, 842] vs. 445 [369, 508] vs. 213 [151, 231], P = 0.006) and hsTnT (0.020 [0.014, 0.038] vs. 0.017 [0.012, 0.022] vs. 0.012 [0.008, 0.014], P = 0.007) compared to non-PH group and control group, respectively. PH patients showed an increased incidence of fatigue, weight loss, and recurrent infections compared to non-PH patients (35.2% vs. 16.1%, P = 0.01) (Table 1).

3.3 Echocardiographic and hemodynamic characteristics

The echocardiographic and hemodynamic data are shown in Table 2. No significant differences in LVEF and RV wall dimension were seen between the three groups (P > 0.05). Moreover, no significant differences in the frequency of PDA (28.0% vs. 29.6%, P = 0.13) or VSD (72.0% vs. 70.4%, P = 0.16) were observed between the PH and non-PH groups. PH patients had higher RV wall dimension z-scores (0.65 ± 0.78 vs. −0.31 ± 0.42 vs. −0.66 ± 0.26, P = 0.01) compared to non-PH patients and controls. Mean RAP (6.1 ± 0.84 vs. 4.1 ± 0.42, P < 0.001), PASP (46.2 ± 6.5 vs. 26.8 ± 2.7, P < 0.001), mean PAP (31.7 ± 4.9 vs. 16.4 ± 3.1, P < 0.001), PVR index (4.9 ± 1.4 vs. 2.3 ± 0.41, P < 0.001) and Qp/Qs (1.86 ± 0.39 vs. 1.36 ± 0.14, P < 0.001) were all significantly higher in PH compared to non-PH patients (Table 2).

3.4 Clinical and hemodynamic correlations

The correlation of echocardiographic and hemodynamic data with biomarker levels are summarized in Table 3. LCN2 was significantly correlated with mean RAP (r = 0.572, P < 0.001), PASP (r = 0.651, P < 0.001), mean PAP (r = 0.689, P < 0.001), PVR index (r = 0.256, P = 0.03), Qp/Qs (r = 0.297, P = 0.01) and RV wall dimension z-scores (r = 0.247, P = 0.01), but not with LVEF (r = −0.126, P = 0.15). HsTnT levels showed a significant correlation with mean PAP (r = 0.265, P = 0.02), PASP (r = 0.298, P = 0.03), and PVR index.
Table 1. Demographical and clinical data of the study population.

|                      | Controls (n = 23) | Non-PH group (n = 25) | PH group (n = 54) | P value |
|----------------------|------------------|-----------------------|-------------------|---------|
| Age, months, median (IQR) | 11 (7.5, 12)     | 10 (6, 12)            | 11 (7, 14)        | 0.31    |
| Female, sex, n (%)     | 7 (30.4%)        | 7 (28.0%)             | 17 (31.5%)        | 0.17    |
| Body surface area, m²  | 0.43 ± 0.08      | 0.42 ± 0.07           | 0.41 ± 0.06       | 0.23    |
| Symptomatic, n (%)     | -                | 4 (16.1%)             | 19 (35.2%)        | 0.01    |
| History of AKI, n (%)  | -                | 1 (4%)                | 2 (3.7%)          | 0.16    |
| Creatinine, mg/dL      | 29.9 ± 6.2       | 29.6 ± 6.3            | 31.4 ± 5.8        | 0.16    |
| Urea nitrogen, mmol/L  | 3.5 ± 1.2        | 3.7 ± 0.8             | 4.0 ± 1.3         | 0.27    |
| NT-proBNP, ng/L, median (IQR) | 213 (151, 231) | 445 (369, 508)       | 569 (431, 842)    | 0.006   |
| HsTnT, ng/L, median (IQR) | 0.012 (0.008,0.014) | 0.017 (0.012,0.022) | 0.020 (0.014,0.038) | 0.007  |
| LCN2, pg/mL, median (IQR) | 5.3 (4.6, 6.6) | 6.2 (5.3, 8.9)       | 9.2 (5.9, 12.3)   | <0.001  |

PH, pulmonary hypertension; IQR, interquartile range; AKI, acute kidney injury; NT-proBNP, N-Terminal pro Brain Natriuretic Peptide; hsTnT, high-sensitive cardiac troponin T; LCN2, lipocamlin 2.

Table 2. Echocardiographic and haemodynamic data of the study population.

|                      | Controls (n = 23) | Non-PH group (n = 25) | PH group (n = 54) | P value |
|----------------------|------------------|-----------------------|-------------------|---------|
| LVEF, %              | 70 ± 3.0         | 71 ± 4.1              | 69 ± 4.3          | 0.21    |
| RV wall dimension, mm | 2.8 ± 0.11       | 3.0 ± 0.21            | 3.2 ± 0.25        | 0.09    |
| RV wall dimension z-score | −0.66 ± 0.26     | −0.31 ± 0.42          | 0.65 ± 0.78       | 0.01    |
| PH associated with PDA, n (%) | -                | 7 (28.0%)             | 16 (29.6%)        | 0.13    |
| PH associated with VSD, n (%) | -                | 18 (72.0%)            | 32 (70.4%)        | 0.16    |
| Mean RAP, mmHg       | -                | 4.1 ± 0.42            | 6.1 ± 0.84        | 0.001   |
| PASP, mmHg           | -                | 26.8 ± 2.7            | 46.2 ± 6.5        | 0.001   |
| Mean PAP, mmHg       | -                | 16.4 ± 3.1            | 31.7 ± 4.9        | 0.001   |
| PVR index, WU × m²   | -                | 2.3 ± 0.41            | 4.9 ± 1.4         | 0.001   |
| Qp/Qs                | -                | 1.36 ± 0.14           | 1.86 ± 0.39       | 0.02    |

PH, pulmonary hypertension; LVEF, Left ventricular ejection fraction; RV, right ventricular; PDA, patent ductus arteriosus; VSD, ventricular septal defect; RAP, right atrial pressure; PASP, pulmonary artery systolic pressure; PAP, pulmonary artery pressure; PVR, pulmonary vascular resistance; WU, Wood units; Qp, pulmonary flow; Qs, systemic flow.

(r = 0.287, P = 0.01). However, a significant correlation was not observed with RV wall dimension z-score (r = 0.126, P = 0.12), LVEF (r = −0.134, P = 0.13), mean RAP (r = 0.156, P = 0.09) or Qp/Qs (r = 0.129, P = 0.15). NT-proBNP levels showed significant correlations with mean RAP (r = 0.278, P = 0.01), PASP (r = 0.304, P = 0.01), mean PAP (r = 0.292, P = 0.01), and PVR index (r = 0.239, P = 0.03) and Qp/Qs (r = 0.273, P = 0.02), but not with LVEF (r = −0.107, P = 0.23) or RV wall dimension z-score (r = 0.146, P = 0.10) (Table 3).

3.5 Predictors of the development of PH

In univariate logistic regression, LCN2 (OR = 2.69 [1.06–5.31], P < 0.001), NT-proBNP (OR = 1.91 [1.21–7.56], P = 0.03) and hsTnT (OR = 1.36 [1.01–1.37], P = 0.01) were associated with PH (Table 4). In ROC curve analysis for prediction of PH, NT-proBNP showed an AUC of 0.69 (P = 0.006). A cutoff value of ≥521 ng/L predicted PH with 63.8% sensitivity and 56.4% specificity. hsTnT showed an AUC of 0.62 (P = 0.045) and a cutoff value of ≥0.029 ng/mL predicted PH with 56.9% sensitivity and 55.1% specificity. LCN2 showed a higher AUC of 0.81 (P < 0.001), and a cutoff value of ≥8.1 pg/mL predicted PH with 76.9% sensitivity and 91.8% specificity (Fig. 1). When LCN2, NT-proBNP and hsTnT were included in a multivariate analysis, only LCN2 (OR = 1.68 [1.04–4.52], P = 0.03) remained independently associated with PH.

4. Discussion

The three important findings from this study are: (1) pediatric patients with PH and associated CHD had higher levels of LCN2; (2) the LCN2 level was significantly correlated with invasive indices of PH; and (3) LCN2, hsTnT and NT-proBNP may all be predictors of PH, but only LCN2 was independently associated with PH in multivariate regression analysis.

Previous studies showed that LCN2 may play a role in the pathogenesis of PH in children with CHD. However, most of these studies focused on gene expression at the molecular level. The predictive value of LCN2 for PH in the clinical setting remains unknown [15, 21]. In this study, we found the concentration of LCN2 was greater in CHD patients with PH compared to those without PH. Takahashi and coworkers [16] found increased LCN2 expression in dermal microvascular endothelial cells and speculated this may contribute to
Table 3. Correlation of echocardiographic and hemodynamic data with biochemical marker levels.

|                         | LCN2 | hsTnT | NT-proBNP |
|-------------------------|------|-------|-----------|
|                         | r value | P value | r value | P value | r value | P value |
| LVEF                   | -0.126 | 0.15 | -0.134 | 0.13 | -0.107 | 0.23 |
| RV wall dimension z-score | 0.247 | 0.01 | 0.126 | 0.12 | 0.146 | 0.10 |
| Mean RAP, mmHg          | 0.572 | 0.001 | 0.156 | 0.09 | 0.278 | 0.01 |
| PASP, mmHg              | 0.651 | 0.001 | 0.298 | 0.03 | 0.304 | 0.01 |
| Mean PAP, mmHg          | 0.689 | 0.001 | 0.265 | 0.02 | 0.292 | 0.01 |
| PVR index, WU × m²      | 0.256 | 0.03 | 0.287 | 0.01 | 0.239 | 0.03 |
| Qp/Qs                   | 0.297 | 0.01 | 0.129 | 0.15 | 0.273 | 0.02 |

LCN2, Lipocalin 2; hsTnT, high-sensitive cardiac troponin T; NT-proBNP, N-Terminal pro Brain Natriuretic Peptide; LVEF, left ventricular ejection fraction; RV, right ventricular; RAP, right atrial pressure; PASP, pulmonary artery systolic pressure; PAP, pulmonary artery pressure; PVR, pulmonary vascular resistance; WU, Wood units; Qp, pulmonary flow; Qs, systemic flow.

Table 4. Predictors for the development of pulmonary hypertension.

| Variables               | Odds ratio (95% CI) | P value |
|------------------------|---------------------|---------|
| Gender (Female)        | 3.65 (0.89–16.3)    | 0.68    |
| Age, months            | 1.26 (0.91–2.38)    | 0.12    |
| NT-proBNP              | 1.91 (1.21–7.56)    | 0.03    |
| Lipocalin 2            | 2.69 (1.06–6.31)    | <0.001  |
| hsTnT                  | 1.36 (1.01–3.57)    | 0.01    |
| RV wall dimension z-score | 1.19 (0.85–2.76) | 0.06    |

NT-proBNP, N-terminal pro B-type natriuretic peptide; hsTnT, high-sensitive cardiac troponin T; RV, right ventricular.

PH progression in systemic sclerosis. Li et al. [22] found LCN2 to be the only gene significantly expressed in females with PH. In our study, increased expression of LCN2 was associated with PH and hence we postulate this may explain the increased incidence of pulmonary vascular disease associated with CHD. Another major result from our study was the positive correlation of LCN2 with invasive indices of PH such as mean PAP, PASP and PVR index. This contrasts with the findings of Takahashi and coworkers in systemic sclerosis patients with PH, who reported an inverse relation between LCN2 levels and RV systolic pressure in patients with normal renal function [16]. These discordant results could be due to the different etiologies and mechanisms in the development of PH.

Our results also showed significantly higher serum hsTnT levels in patients with PH compared to those without PH, as also noted by Kayali et al. [23]. Ventricular hypertrophy in response to higher ventricular pressure limits myocardial perfusion and increases oxygen demand, leading to a higher risk of myocardial injury and increased troponins [24]. In the present study, PH patients had a greater prevalence of RV hypertrophy compared to patients without PH. In the pediatric population, increased hsTnT levels may reflect underlying myocardial damage resulting from pressure or volume overload. Serum hsTnT may therefore be a useful predictor of myocardial injury in pediatric cases with PH due to CHD.

Earlier workers found that NT-proBNP could be used to assess risk in PH patients [3, 8]. It has previously been reported that NT-proBNP was associated with a worse outcome in PH children who underwent surgery for CHD [5, 7]. Our results agree with a previous study [23] that found significant correlations between NT-proBNP levels and hemodynamic indices of PH. Elevated NT-proBNP might be explained by the pathological stretching of cardiac myocytes as a result of volume and pressure overloading because of the left-to-right shunt. These findings suggest that serum NT-proBNP might serve as a useful biomarker to detect heightened wall tension resulting from increased pulmonary flow in pediatric patients with CHD-associated PH.

Previous animal and clinical studies showed that LCN2 has major roles in the remodeling of pulmonary arterioles and the
progression of PH. However, the association between LCN2 and the development of PH has not been thoroughly investigated [16, 22]. Our results showed that LCN2 was independently associated with PH. This may be because LCN2 promotes stress of the endoplasmic reticulum by increasing the amount of intracellular iron in human pulmonary arterial smooth muscle cells [21]. Another explanation might be that LCN2 inhibits the apoptosis of pulmonary artery smooth muscle cells induced by oxidative stress via a decrease in intracellular ROS and elevation of SODs. A previous animal study found significantly elevated LCN2 levels in a rat PH model induced with monocrotaline [15]. These studies support our conclusion that pediatric CHD patients with higher levels of serum LCN2 have an increased risk of developing PH. The relationship between LCN2 and PH provides a novel and important insight into the clinical management of pediatric CHD patients with PH.

5. Limitations

Our study has several limitations. First, the study population is small and from a single center. Secondly, heart catheterization is an invasive procedure and hence the relationship between LCN2 and hemodynamic measures could not be evaluated longitudinally. Finally, serial measurements of LCN2 levels were not performed. Further studies that focus on changes in LCN2 levels over time and on disease progression, as well as longer patient follow up periods should help to shed more light on the role of LCN2 in this population.

6. Conclusions

The current study demonstrated that children with PH have alterations in LCN2 expression and that LCN2 levels positively correlated with invasive indices of PH. LCN2 could help in predicting the presence of PH in pediatric CHD cases. Further studies that include changes in LCN2 levels over time, larger sample size and longer patient follow up are required to substantiate these findings.

Author contributions

HJZ: Conceptualization, methodology, writing-original draft and funding acquisition. TS: Conceptualization, data curation and formal analysis. JY: Methodology, resources and software. YS: Resources and validation and visualization. GWL: Investigation, validation and formal analysis. CK: Methodology, validation and formal analysis. EAEA: Conceptualization, writing-reviewing and editing. RGBC: Methodology and writing-editing. LYX: Investigation and visualization. ZKY: Resources, software and validation. ZQL: Resources, writing-reviewing and validation. NM: Conceptualization, methodology, writing-reviewing, editing and funding acquisition. RGBC: Methodology and writing-editing. LYX: Investigation and visualization. ZKY: Resources, software and validation. YS: Resources and validation and visualization. GK: Methodology, validation and formal analysis. YL: Resources and visualization. ZQS: Resources, writing-reviewing and validation. NM: Conceptualization, methodology, writing-reviewing, editing and funding acquisition.

Ethics approval and consent to participate

The research protocol was approved by the human research ethics committee of the Beijing Children’s Hospital (approval ID: IR.IEC-C-008-A08-V.03.2). Informed consent was obtained from the patient’s guardian(s). The study was performed in accordance with the Declaration of Helsinki.

Acknowledgment

The authors thank all the staff members who participated in data collection for their contribution to the current study.

Funding

This research was supported by the National Science Foundation of Beijing Municipality under Grant NO. 719062 and Grant NO. 7202046; the National Natural Science Foundation of China under Grant No. 81641071.

Conflict of interest

The authors declare no conflict of interest.

References

[1] van Dissel AC, Blok IM, Zwinderman AH, van Dijk APJ, Duijnhouwer AL, de Winter RJ, et al. Prognostic value of multiple repeated biomarkers in pulmonary arterial hypertension associated with congenital heart disease. European Journal of Heart Failure. 2019; 21: 249–251.
[2] Lammers AE, Aptiz C, Zartner P, Hager A, Dubowy K, Hansmann G. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016; 102: i1i–i13.
[3] Giannakoulas G, Mouratoglou S, Gatouzis MA, Karvounis H. Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. A systematic review. International Journal of Cardiology. 2014; 174: 618–623.
[4] Geenen LW, Bagnen VJM, Koustaal T, Boomers KA, Eindhoven JA, Boersma E, et al. The prognostic value of various biomarkers in adults with pulmonary hypertension: a multi-biomarker approach. American Heart Journal. 2019; 208: 91–99.
[5] Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galié N, et al. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients with Pulmonary Arterial Hypertension. Circulation. 2019; 139: 2440–2450.
[6] Schuuring MJ, van Riel ACMJ, Vis JC, Dufelts MG, van Straalen JP, Boekholtz SM, et al. High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease. Congenital Heart Disease. 2013; 8: 520–526.
[7] Said F, Haarman MG, Rooftshoof MTR, Hillege HL, Ploegstra M, Berger RMF. Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children. Journal of Pediatrics. 2020; 220: 139–145.
[8] Bosello S, De Luca G, Berardi G, Canestrari G, de Waure C, Gabrielli FA, et al. Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: a prospective study. European Journal of Internal Medicine. 2019; 60: 46–53.
[9] Yildiz M, Sahin A, Behnes M, Akin I. An Expanding Role of Biomarkers in Pulmonary Arterial Hypertension. Current Pharmaceutical Biotechnology. 2017; 18: 491–494.
[10] Kirbiš S, Gorenjak M, Sinkovič A. The role of urine neutrophil gelatinase-associated lipocalin (NGAL) in acute heart failure in patients with ST—elevation myocardial infarction. BMC Cardiovascular Disorders. 2015; 15: 49.

[11] Marques FZ, Prestes PR, Byars SG, Ritchie SC, Würtz P, Patel SK, et al. Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and Heart Failure. Journal of the American Heart Association. 2017; 6: e005971.

[12] Gencer M, Gazi E, Hacıvelioğlu S, Binnetoğlu E, Barutçu A, Türkön H, et al. The relationship between subclinical cardiovascular disease and lipocalin-2 levels in women with PCOS. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2014; 181: 99–103.

[13] Ataei N, Ameli S, Yousefifard M, Oraei A, Ataei F, Bazargani B, et al. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C in Early Detection of Pediatric Acute Kidney Injury; a Diagnostic Accuracy Study. Emergency. 2018; 6: e2.

[14] Yoneyama F, Okamura T, Takigiku K, Yasukouchi S. Novel Urinary Biomarkers for Acute Kidney Injury and Prediction of Clinical Outcomes after Pediatric Cardiac Surgery. Pediatric Cardiology. 2020; 41: 695–702.

[15] Wang G, Liu X, Meng L, Liu S, Wang L, Li J, et al. Up-regulated lipocalin-2 in pulmonary hypertension involving in pulmonary artery SMC resistance to apoptosis. International Journal of Biological Sciences. 2014; 10: 798–806.

[16] Takahashi T, Asano Y, Noda S, Aozasa N, Akamata K, Taniguchi T, et al. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis. British Journal of Dermatology. 2015; 173: 681–689.

[17] Sugimoto M, Kuwata S, Kurishima C, Kim JH, Iwamoto Y, Senzaki H. Cardiac biomarkers in children with congenital heart disease. World Journal of Pediatrics. 2015; 11: 309–315.

[18] Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019; 53: 1801913.

[19] Lang RM, Badano LP, Mor-Avi V, Afifao J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging. 2015; 16: 233–270.

[20] Koestenberger M, Ravekes W, Everett AD, Stueger HP, Heinzl B, Gamillscheg A, et al. Right Ventricular Function in Infants, Children and Adolescents: Reference Values of the Tricuspid Annular Plane Systolic Excursion (TAPSE) in 640 Healthy Patients and Calculation of z Score Values. Journal of the American Society of Echocardiography. 2009; 22: 715–719.

[21] Wang G, Liu S, Wang L, Meng L, Cui C, Zhang H, et al. Lipocalin-2 Promotes Endoplasmic Reticulum Stress and Proliferation by Augmenting Intracellular Iron in Human Pulmonary Arterial Smooth Muscle Cells. International Journal of Biological Sciences. 2017; 13: 135–144.

[22] Li C, Zhang Z, Xu Q, Wu T, Shi R. Potential mechanisms and serum biomarkers involved in sex differences in pulmonary arterial hypertension. Medicine. 2020; 99: e19612.

[23] Kayali S, Ertugrul I, Yildas T, Kaya O, Ozgür S, Orrin UA, et al. Sensitive Cardiac Troponins: could they be New Biomarkers in Pediatric Pulmonary Hypertension Due to Congenital Heart Disease? Pediatric Cardiology. 2018; 39: 718–725.

[24] Sugimoto M, Ota K, Kajihama A, Nakau K, Manabe H, Kajino H. Volume Overload and Pressure Overload due to Left-to-Right Shunt-Induced Myocardial Injury. Evaluation Using a Highly Sensitive Cardiac Troponin-i Assay in Children with Congenital Heart Disease. Circulation Journal. 2011; 75: 2213–2219.